diabet
nephropathi
dn
common
caus
endstag
kidney
diseas
worldwid
associ
increas
morbid
mortal
patient
type
type
diabet
recent
evid
reveal
dipeptidyl
inhibitor
may
exhibit
protect
effect
dn
fact
kidney
organ
activ
highest
level
per
organ
weight
preclin
analysi
reveal
inhibitor
also
amelior
kidney
fibrosi
review
analyz
recent
report
field
explor
renoprotect
effect
possibl
mechan
inhibitor
diabet
mellitu
becom
major
global
health
issu
number
peopl
diabet
worldwid
expect
rise
million
million
accord
intern
diabet
feder
diabet
nephropathi
dn
one
devast
complic
diabet
risk
dn
tightli
link
poor
glucos
control
type
type
diabet
associ
hyperglycemia
impact
hyperglycemia
gener
mediat
divers
metabol
pathway
includ
increas
reactiv
oxygen
speci
format
excess
product
advanc
glycat
end
product
age
activ
polyol
protein
kinas
c
pkc
hexosamin
pathway
activ
pathway
lead
complex
dysregul
variou
effector
molecul
result
cellular
damag
dysfunct
experiment
studi
shown
pathophysiolog
mechan
may
modifi
dipeptidyl
inhibit
preclin
studi
also
suggest
inhibitor
provid
renoprotect
beyond
lower
glucos
level
proteinprotein
interact
proteolyt
antioxid
properti
review
focu
possibl
mechan
inhibitor
combat
diabet
nephropathi
especi
kidney
fibrosi
cell
surfac
aminopeptidas
origin
character
cell
differenti
antigen
multifunct
protein
exert
divers
biolog
activ
proteas
activ
associ
adenosin
deaminas
ada
interact
extracellular
matrix
cell
surfac
coreceptor
activ
mediat
viral
entri
regul
intracellular
signal
transduct
coupl
control
cell
migrat
prolifer
express
ubiquit
found
mani
cell
type
includ
endotheli
cell
multipl
vascular
bed
render
enzym
highli
access
peptid
substrat
circul
gut
liver
lung
kidney
member
serin
peptidaseprolyl
oligopeptidas
gene
famili
member
famili
often
classifi
subgroup
accord
structur
function
includ
membranebound
peptidas
fibroblast
activ
protein
fap
sepras
resid
cytoplasm
enzym
nonenzymat
peptidas
complex
action
amplifi
panopli
bioactiv
substrat
turn
act
eleg
biochem
messeng
multipl
tissu
includ
immun
neuroendocrin
system
peptid
substrat
identifi
includ
glucagonlik
glucosedepend
insulinotrop
peptid
gip
brain
natriuret
peptid
neuropeptid
high
mobil
group
protein
other
transmit
signal
across
cell
membran
interact
membran
protein
gene
encod
type
ii
transmembran
protein
amino
acid
anchor
lipid
bilay
singl
hydrophob
segment
locat
nterminu
short
cytoplasm
tail
six
amino
acid
extracellular
portion
contain
glycosyl
domain
cysteinerich
domain
catalyt
domain
mutat
studi
demonstr
ctermin
loop
essenti
dimer
format
catalyt
efficaci
analysi
crystal
structur
reveal
also
form
tetram
two
solubl
protein
two
membranebound
protein
interact
may
influenc
effici
entri
cleavag
substrat
catalyt
site
allow
cellcel
commun
catalyt
activ
liber
plasma
membran
produc
solubl
circul
form
aa
lack
intracellular
tail
transmembran
region
account
substanti
proport
activ
human
serum
membranebound
contain
residu
wherea
contain
residu
lack
cytoplasm
domain
residu
transmembran
domain
residu
flexibl
stalk
residu
fig
activ
intracellular
signal
pathway
increas
prolifer
human
lymphocyt
independ
either
catalyt
activ
bind
ada
impair
insulinmedi
activ
akt
human
adipocyt
skelet
muscl
smooth
muscl
cell
vitro
howev
mechan
activ
signal
transduct
poorli
understood
activ
subject
regul
mani
level
includ
control
gene
protein
express
interact
bind
partner
modul
enzym
activ
import
cytokin
regul
activ
demonstr
chronic
b
lymphocyt
leukemia
cell
lead
upregul
intracellular
cell
surfac
express
well
activ
cell
surfac
intracellular
express
also
highli
regul
often
express
low
level
basal
condit
markedli
induc
stimul
cell
activ
mitogen
antigen
stimuli
control
shed
gener
poorli
understood
lamer
et
al
found
insulin
increas
releas
although
chang
express
mrna
human
adipocyt
isol
viscer
depot
studi
focus
origin
found
kidney
extract
exhibit
highest
activ
howev
import
sourc
bone
marrow
kidney
studi
highlight
limit
understand
cell
type
tissu
contribut
gener
activ
plasma
vivo
character
cell
evalu
addit
sourc
mechan
releas
requir
addit
studi
gener
incretin
group
metabol
hormon
stimul
decreas
blood
glucos
level
either
increas
insulin
releas
reduc
gastrointestin
absorpt
prototyp
incretin
intestin
gip
hormon
gip
rapidli
inactiv
enzym
therefor
welldocu
drug
target
treatment
type
diabet
pharmacolog
inhibit
result
accumul
stimul
insulin
secret
contribut
reduct
postprandi
hyperglycemia
recent
benefici
pleiotrop
effect
inhibitor
report
clinic
research
preclin
experi
two
type
inhibitor
use
clinic
dipeptid
structur
mimet
nonpeptidomimet
first
type
includ
sitagliptin
approv
fda
vildagliptin
approv
european
medicin
agenc
saxagliptin
approv
fda
nonpeptidomimet
includ
linagliptin
xanthinebas
approv
fda
alogliptin
modifi
pyrimidinedion
approv
fda
small
molecul
rapidli
absorb
follow
oral
dose
result
greater
inhibit
activ
full
period
typic
drug
rais
peripher
plasma
concentr
intact
form
incretin
twoto
threefold
although
class
differ
wide
chemistri
select
clinic
proof
concept
inhibit
diabet
patient
first
report
inhibitor
significantli
reduc
fast
plasma
glucos
level
studi
express
posit
correl
amount
viscer
adipos
tissu
adipocyt
size
inflamm
level
neg
correl
glucos
infus
rate
euglycemichyperinsulinem
clamp
efficaci
inhibitor
reduc
glycemia
weaker
sulfonylurea
insulin
thiazolidinedion
significantli
better
toler
produc
weight
gain
furthermor
inhibitor
benefit
patient
recent
develop
diabet
also
patient
longstand
diabet
addit
glucoselow
action
inhibitor
demonstr
play
protect
role
cardiovascular
diseas
includ
hypertens
abdomin
aortic
aneurysm
cardiomyopathi
atherosclerosi
peripher
vascular
diseas
via
pathway
due
divers
wide
distribut
pleiotrop
action
mani
vivo
vitro
studi
also
found
inhibitor
prevent
organ
fibrosi
includ
cardiac
fibrosi
hepat
fibrosi
kidney
fibrosi
local
surfac
mani
cell
type
includ
endotheli
cell
kidney
epitheli
cell
cell
bind
partner
transmit
intracellular
signal
fact
kidney
express
highest
level
per
organ
weight
moreov
mammalian
kidney
high
concentr
express
increas
cultur
human
renal
glomerular
epitheli
cell
inflamm
rat
model
type
diabet
mellitu
sever
candid
effect
inhibitor
kidney
identifi
includ
known
substrat
cleavag
meprin
neuropeptid
npi
peptid
yy
pyy
thu
research
demonstr
increas
activ
kidney
urin
hallmark
human
glomerular
diseas
inhibitor
analyz
confirm
role
kidney
anim
model
reduct
albuminuria
improv
histolog
chang
kidney
observ
model
treat
vildagliptin
model
treat
sitagliptin
signific
reduct
urinari
albumin
excret
also
observ
diabet
endotheli
nitric
oxid
synthas
knockout
mice
treat
linagliptin
addit
ang
ii
receptor
antagonist
experiment
model
renal
ischemiareperfus
injuri
treat
vildagliptin
inhibit
produc
nephroprotect
effect
mediat
antiapoptot
antiinflammatori
antioxid
effect
linagliptin
recent
approv
inhibitor
exhibit
nonlinear
pharmacokinet
properti
less
dose
proport
profil
almost
complet
elimin
via
enter
system
less
found
urin
human
shown
linagliptin
significantli
reduc
urinari
albumin
excret
patient
week
treatment
pharmacokinet
profil
linagliptin
administr
show
accumul
linagliptin
follow
multipl
mgday
dose
signific
chang
control
diabet
subject
regardless
renal
function
antifibrot
properti
inhibitor
also
shown
model
kidney
fibrosi
unilater
ureter
obstruct
uuo
model
administr
novel
inhibitor
result
signific
decreas
albuminuria
urinari
excret
renal
fibrosi
newest
studi
found
linagliptin
restor
normal
kidney
structur
streptozotocin
stz
induc
diabet
kidney
fibrosi
mice
without
alter
blood
pressur
bodi
weight
blood
sugar
level
organ
weight
kidney
liver
heart
compar
untreat
diabet
mice
transform
growth
factor
primari
cytokin
drive
fibrosi
kidney
organ
suscept
fibrot
injuri
lung
liver
member
superfamili
transduc
intracellular
signal
smad
protein
studi
demonstr
signal
mediat
renal
fibrosi
inhibitor
may
amelior
diabet
nephropathi
reduc
overproduct
renoprotect
attribut
inhibit
activ
mimic
incretin
action
activ
previou
studi
stzinduc
diabet
mice
treat
inhibitor
linagliptin
exhibit
suppress
activityprotein
express
amelior
kidney
fibrosi
associ
inhibit
endothelialtomesenchym
transit
endmt
phosphoryl
endmt
first
discov
heart
develop
confirm
crucial
import
form
valv
septa
heart
embryogenesi
endmt
contribut
accumul
activ
fibroblast
myofibroblast
kidney
fibrosi
fibroblast
key
mediat
fibrosi
kidney
organ
chronic
kidney
diseas
ckd
associ
increas
circul
angiogenesi
inhibitor
impact
prolifer
apoptosi
cardiac
endotheli
cell
promot
endmt
lead
cardiac
fibrosi
capillari
rarefact
endmt
involv
kidney
fibrosi
progress
zeisberg
et
al
confirm
endmt
also
involv
heart
tumor
progress
regard
linagliptin
could
exhibit
antifibrot
effect
mechan
specif
target
endotheli
cell
essenti
receptor
heterodimer
subsequ
intracellular
signal
transduct
includ
level
proteinprotein
interact
critic
signal
transduct
found
format
heterodim
suppress
sirnatransfect
endotheli
cell
compar
cell
transfect
control
sirna
uuo
model
inhibitor
reduc
level
inflammatori
fibrot
marker
phosphoryl
tolllik
receptor
nadph
nuclear
factor
kappa
b
result
suggest
activ
kidney
import
role
signal
progress
renal
diseas
target
therapi
inhibit
may
prove
use
new
approach
manag
progress
renal
diseas
includ
kidney
fibrosi
integrin
exist
heterodim
form
exhibit
differ
ligand
bind
signal
properti
integrin
subunit
consist
extracellular
domain
determin
ligand
bind
properti
transmembran
domain
short
cytoplasm
tail
bind
multipl
cytosol
transmembran
protein
form
focal
adhes
except
integrin
bind
extracellular
matrix
ecm
glycoprotein
includ
collagen
fibronectin
laminin
cellular
receptor
vascular
cell
adhes
member
intercellular
cell
adhes
molecul
icam
famili
addit
integrin
also
play
key
role
assembl
actin
cytoskeleton
well
modul
signal
transduct
pathway
control
biolog
cellular
function
includ
cell
adhes
migrat
prolifer
cell
differenti
apoptosi
integrin
abl
transduc
signal
intracellularli
follow
ligand
bind
outsidein
signal
unlik
cell
receptor
integrin
shift
highand
lowaffin
conform
ligand
bind
insideout
signal
depend
cell
type
integrin
either
basal
activ
case
adher
cell
attach
basement
membran
basal
inact
case
platelet
leukocyt
freeli
circul
activ
undergo
platelet
aggreg
mediat
inflammatori
respons
respect
integrin
kinas
activ
instead
provid
connect
ecm
actin
cytoskeleton
connect
allow
integrin
regul
cytoskelet
organ
cell
motil
well
alter
flux
mani
intracellularsign
pathway
includ
cell
surviv
cell
prolifer
cell
shape
angiogenesi
thu
integrin
critic
maintain
cellular
homeostasi
trigger
number
signal
pathway
normal
condit
patholog
condit
integrin
associ
wide
varieti
renal
patholog
includ
obstruct
nephropathi
dn
among
member
integrin
famili
critic
given
pair
differ
make
receptor
mani
type
stimuli
fig
integrin
ubiquit
express
bind
multipl
partner
thu
surpris
knockout
result
embryon
lethal
due
complet
inhibit
preimplant
develop
contrast
knockout
integrin
subunit
exclus
heterodimer
function
primari
collagen
receptor
viabl
fertil
possess
distinct
characterist
abnorm
focal
adhes
kinas
fak
essenti
intracellular
integr
integrin
signal
pathway
abnorm
redistribut
decreas
express
integrin
fak
import
molecular
event
regul
function
podocyt
abnorm
hemodynam
condit
express
integrin
fibroblast
requir
fibrogenesi
block
integrin
signal
diminish
progress
cutan
fibrosi
yeh
et
al
found
express
mrna
protein
significantli
upregul
uuo
mice
accompani
correspond
elev
tubular
express
inhibit
signal
reduc
level
amelior
fibrosi
demonstr
strong
correl
express
within
tubulointerstitium
presenc
tubulointerstiti
fibrosi
hamzeh
et
al
also
found
absenc
human
proxim
tubular
cell
fail
activ
signal
cascad
would
lead
synthesi
profibrot
protein
ultim
develop
renal
fibrosi
also
show
cyclic
stretchinduc
fibronectin
express
mediat
csrcand
pathway
renal
epitheli
cell
loss
cell
surfac
express
shown
associ
decreas
phosphoryl
integrin
residu
key
role
cellular
adhes
ecm
recent
publish
paper
identifi
new
profibrot
molecular
mechan
associ
interact
integrin
fig
endmt
inhibit
integrin
delet
addit
integrin
defici
result
inhibit
heterodimer
final
interact
integrin
induc
vascular
endotheli
growth
factorreceptor
vegfr
express
concomit
suppress
level
relev
vegf
promin
stimulu
endotheli
cell
angiogenesi
endotheli
cell
respons
toward
vegf
modul
distinct
vegf
receptor
favor
endmt
wherea
counteract
endmt
result
indic
interact
integrin
may
therapeut
target
kidney
fibrosi
diabet
cumul
effect
hyperglycemia
inflammatori
cytokin
proteinuria
age
high
blood
pressur
hypoxia
result
alter
mirna
express
profil
alter
mirna
level
initi
transit
program
normal
kidney
ultim
lead
fibrosi
microrna
mir
discov
year
ago
action
synthesi
mir
tightli
regul
key
antifibrot
mir
involv
suppress
import
understand
fibrot
mechan
diabet
kidney
accord
predict
microrna
target
targetscan
http
identifi
bind
site
clone
util
report
vector
contain
legend
human
mrna
confirm
bind
site
neg
regul
gene
express
diabet
kidney
increas
level
associ
suppress
compar
normoglycem
kidney
fig
linagliptin
inhibitor
amelior
kidney
function
induc
express
diabet
kidney
model
quantit
analysi
reveal
fig
integrin
receptor
ligand
integrin
famili
critic
given
pair
differ
make
receptor
mani
type
stimuli
microrna
b
c
suppress
diabet
kidney
compar
control
kidney
linagliptin
restor
diabetessuppress
microrna
level
similarli
level
restor
linagliptin
vitro
fig
molecul
exhibit
similar
antifibrot
mechan
antiendmt
smad
signal
effect
microrna
array
analysi
kidney
sampl
reveal
express
famili
microrna
suppress
diabet
kidney
blockad
fgf
signal
induc
endmt
program
mimick
mirna
inhibit
fgf
receptormicrorna
famili
axi
suppress
receptor
level
inhibitor
shown
inhibit
endmt
thu
may
regul
express
level
diabet
kidney
addit
microrna
shown
import
role
endmt
kidney
fibrosi
regul
microrna
inhibitor
must
analyz
determin
detail
mechan
kidney
fibrosi
zucker
diabet
fatti
rat
model
takai
et
al
found
signific
differ
blood
glucos
plasma
insulin
concentr
sitagliptinand
linagliptintr
group
activ
plasma
vascular
tissu
linagliptintr
group
significantli
lower
sitagliptintr
group
anoth
studi
found
local
nucleu
nuclear
transloc
enhanc
monoclon
antibodi
suggest
inhibit
help
cell
surfac
move
nucleu
data
suggest
express
membran
nucleu
although
everi
inhibitor
display
similar
role
suppress
activ
plasma
tissu
inhibitor
might
exert
uniqu
drugspecif
effect
inde
recent
report
linagliptin
suppress
follow
activ
protein
level
integrin
protein
level
endmt
activ
suppress
sitagliptin
inhibit
none
futur
studi
need
focu
molecular
mechan
inhibitor
differ
organ
cell
present
review
describ
variou
aspect
possibl
mechan
inhibitor
combat
kidney
fibrosi
activ
kidney
import
role
signal
progress
renal
diseas
regul
level
target
inhibit
may
prove
use
new
approach
manag
progress
renal
diseas
includ
kidney
fibrosi
abbrevi
ada
adenosin
deaminas
age
advanc
glycat
end
product
dn
diabet
nephropathi
dipeptidyl
ecm
extracellular
matrix
endmt
endothelialtomesenchym
transit
fak
focal
adhes
kinas
fap
fibroblast
activ
protein
gip
glucosedepend
insulinotrop
peptid
glucagonlik
highmobl
group
protein
icam
intercellular
cell
adhes
molecul
npi
neuropeptid
pkc
protein
kinas
c
transform
growth
uuo
unilater
ureter
obstruct
vegfr
vascular
endotheli
growth
factorreceptor
author
declar
compet
interest
author
contribut
ss
design
studi
wrote
review
manuscript
involv
discuss
dk
made
intellectu
contribut
kk
conceiv
project
provid
intellectu
contribut
guid
manuscript
write
edit
author
read
approv
final
manuscript
fig
fibrosi
diabet
kidney
diabet
kidney
fibrosi
associ
suppress
target
protein
level
process
